To preserve and improve patient visual function
To restore patient autonomy and reduce the financial healthcare burden on society

HORAMA technology will help preserve or improve visual function and delay or halt disease progression in patients with rare ocular diseases, thereby limiting or preventing visual handicap and allowing patients to maintain autonomy.

Given the current lack of approved treatments for these rare diseases, the management of affected patients falls to the society at large. The development of effective therapies would thus allow for a significant reduction in societal and healthcare costs associated with visual impairment.

In most countries, legal blindness is defined as visual acuity of less than 1/10, or defects resulting in a visual field of less than 20 degrees in the better eye with optimal visual correction. Visual loss to this extent has a significant impact on a patient’s ability to perform normal daily activities, diminishing their quality of life.



Horama does not own any office in Australia.

The company was warned that someone, claiming to be Christine Placet or Christen Placet, had contacted australian job seekers.

If you see a job offer matching this description, do not answer.

Horama has filed a complaint.